Search clinical trials for: Lorcaserin Dose #1

Total 19510 results

Eisai Inc.

Completed

Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users

Healthy | Drug Abuse

Canada
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects

Healthy Subjects

China
Institute of Medical Biology, Chinese Academy of...
Guangxi Center for Disease Control and Prevention

Completed

Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV

Poliomyelitis

China
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects

Obesity

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Chiesi Farmaceutici S.p.A.

Completed

Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD (CARSAF)

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
Rutgers, The State University of New Jersey
Centers for Disease Control and Prevention

Completed

Experimentally Testing the Effectiveness of a Campus-based Bystander Intervention

Violence | Helping Behavior | Sexual Assault and Rape | Assaultive Behavior

United States
Eisai Inc.

Available

Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies

Epilepsies, Myoclonic | Drug Resistant Epilepsy
University of Minnesota

Recruiting

Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients

Solid Organ Transplant

United States
Pfizer

Completed

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

Fungal Infection

Netherlands
Johns Hopkins University

Terminated

Evaluating Muscle Weakness Improvement With Lorcaserin in ICU (EMILI)

Sepsis | Muscle Weakness

United States
Scripps Whittier Diabetes Institute
Eisai Inc.

Completed

Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic

Obesity | Overweight | Weight Loss

United States
Eisai Inc.

Completed

Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age

Pharmacokinetics in Obese Adolescents

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment

Renal Impairment

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State

Obesity

United States
University of Pennsylvania
Eisai Inc.

Completed

Lifestyle Modification and Lorcaserin for Weight Loss Maintenance

Obesity

United States
Eisai Inc.

Completed

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

Healthy Participants

United States
Eisai Inc.

Recruiting

A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome (MOMENTUM 1)

Epilepsies, Myoclonic

United States, Canada
Columbia University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); New...

Terminated

Predictors of Lorcaserin-Induced Weight Loss

Overweight and Obesity

United States
Eisai Inc.

Completed

A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age

Obesity

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Effect of Lorcaserin on Cannabis Withdrawal and Self-administration

Cannabis Use

United States
Taiho Pharmaceutical Co., Ltd.

Recruiting

A Study of TAS3731 in Healthy Adults

Healthy Adult Males

Japan
Medy-Tox

Completed

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)

Lateral Canthal Lines | Glabellar Lines

United States, Russian Federation, Germany, Canada, Belgium, United Kingdom
Eisai Inc.

Completed

To Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake (TULIP)

Obesity

United States
Zensun Sci. & Tech. Co., Ltd.
Zensun USA Inc.

Completed

Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure (ZS-01-210)

Chronic Heart Failure

United States
Shanghai Municipal Center for Disease Control and...
Shanghai Institute Of Biological Products

Unknown

Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine

Varicella

China
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects

Pharmacokinetics of ASP1707 | Pharmacodynamics of ASP1707

France
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Terminated

Lorcaserin for Cannabis Use Disorder

Cannabis Use Disorder

United States
Virginia Commonwealth University
Gilead Sciences

Withdrawn

Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL (RIVe-CLL/SLL)

Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma
New York State Psychiatric Institute

Completed

Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder

Cannabis Use Disorder

United States
Oryn Therapeutics, LLC

Completed

Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs

Rheumatoid Arthritis

United States
Eisai Inc.

Completed

BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management

Obesity

United States
Loyola University
National Cancer Institute (NCI)

Active, not recruiting

Transfer of Genetically Engineered Lymphocytes in Melanoma Patients

Melanoma

United States
National Institute on Drug Abuse (NIDA)

Completed

Lorcaserin in the Treatment of Cocaine Use Disorder

Cocaine-Related Disorders

United States
Renibus Therapeutics, Inc.

Completed

Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery (START)

AKI

United States, Australia, Canada
Aronora, Inc.

Completed

Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis

Thrombosis | End Stage Renal Disease

United States
Pharnext SA

Completed

Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT) (PLEO-CMT)

Charcot-Marie-Tooth Disease Type 1A

United States, United Kingdom, Belgium, Canada, France, Netherlands, Spain, Germany
Midwest Biomedical Research Foundation

Unknown

Lorcaserin Intra Venous Cocaine Effects (LIVE)

Cocaine Use Disorders

United States
Ehab L Atallah

Recruiting

XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia

Acute Myeloid Leukemia | T Cell Lymphoblastic Lymphoma | T Cell Acute Lymphoblastic Leukemia

United States
University of Sao Paulo General Hospital

Completed

Impact of Low Dose Fluoroscopy in Ureteroscopy

Ureteral Stone

Brazil
Kanion & Huawe Medicine Co.,Ltd

Terminated

Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients

Obesity

China
Centre Hospitalier Universitaire de Saint Etienne
Sanofi Pasteur, a Sanofi Company; Bioster, a.s.

Completed

Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19 (COVIMMUNAGE)

Covid19

France
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia

Hyperuricemia
Galapagos NV

Completed

Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation) (SAPHIRA2)

Cystic Fibrosis

Belgium, Netherlands
Oryn Therapeutics, LLC

Withdrawn

A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia

COVID-19

United States
Eisai Inc.

Terminated

Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years

Obesity

United States
Medigene AG

Withdrawn

HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myeloproliferative Disorders | Multiple Myeloma | Myelofibrosis | Chronic Myeloid Leukemia | Acute Lymphoid Leukemia | Malignant Lymphoma

Netherlands
Galapagos NV

Completed

Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation) (SAPHIRA1)

Cystic Fibrosis

United Kingdom, Australia, Ireland, Germany, Czech Republic
Eisai Inc.

Completed

BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management

Obesity

United States

Search clinical trials for: Lorcaserin Dose #1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations